Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients.
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.